Drug intelligence / Profile preview

BIOT-NFL-PEG-AuNPs

Development stage
Preclinical
Lead developer
Centre National de la Recherche Scientifique
Modality
Nanoparticles → Drug Delivery Systems, Peptides
Administration
Intravenous
01

Overview

BIOT-NFL-PEG-AuNPs is a **hybrid gold nanoparticle formulation** functionalized with biotinylated NFL-TBS.40-63 peptide and PEG (polyethylene glycol). The NFL-TBS.40-63 peptide specifically destabilizes the microtubule network within target cancer cells, originally demonstrated in glioma and further validated in pancreatic ductal adenocarcinoma (PDAC). Conjugation to gold nanoparticles and PEG enhances cellular uptake, targeting, and optimizes the peptide's anti-tumor effects. In preclinical models, BIOT-NFL-PEG-AuNPs slowed tumor growth, reduced tumor index, exhibited antiangiogenic effects, altered cancer cell metabolism, and modulated the immune response with minimal systemic toxicity. The primary mechanism is disruption of the microtubule cytoskeleton in cancer cells, leading to selective cytotoxicity against tumor cells, especially in PDAC[1][2][3][5].

Other names
NFL-TBS.40-63 peptide gold complex nanovectorbiotinylated NFL-TBS.40-63 peptide PEGylated gold nanoparticles
02

Targets

TUBB (Tubulin (alpha and beta subunits))

Beyond the preview

Go deeper on BIOT-NFL-PEG-AuNPs.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on BIOT-NFL-PEG-AuNPs.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call